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Abstract
Introduction Exogenous prolactin is mitogenic and
antiapoptotic in breast cancer cells, and overexpression of
autocrine prolactin cDNA in breast cancer cell lines has been
shown to stimulate their growth and to protect against
chemotherapy-induced apoptosis. We examined the effects of
the 'pure' prolactin receptor antagonist Δ1–9-G129R-hPrl (Δ1–
9) on the breast cancer cell number and clonogenicity, alone
and in combination with chemotherapy.
Methods The effects of doxorubicin, paclitaxel and Δ1–9 on the
growth of breast cancer cell lines (MCF-7, T47D, MDA-MB-453,
MDA-MB-468 and SK-BR-3) in monolayer culture were
assessed by the sulphorhodamine B assay. Effects on
clonogenicity were assessed by soft agar assay for the cell lines
and by the mammosphere assay for disaggregated primary
ductal carcinoma in situ samples. Dual-fluorescence
immunocytochemistry was used to identify subpopulations of
cells expressing the prolactin receptor and autocrine prolactin.
Results Δ1–9 as a single agent had no effect on the cell number
in monolayer culture, but potentiated the cytotoxic effects of
doxorubicin and paclitaxel. Doxorubicin accordingly induced
expression of prolactin mRNA and protein in all five breast
cancer cell lines tested. Δ1–9 alone inhibited the clonogenicity
in soft agar of cell lines by ~90% and the mammosphere forming
efficiency of six disaggregated primary ductal carcinoma in situ
samples by a median of 56% (range 32% to 88%).
Subpopulations of cells could be identified in the cell lines
based on the prolactin receptor and prolactin expression.
Conclusion Autocrine prolactin appears to act as an inducible
survival factor in a clonogenic subpopulation of breast cancer
cells. The rational combination of cytotoxics and Δ1–9 may
therefore improve outcomes in breast cancer therapy by
targeting this cell population.
Introduction
Exogenous prolactin has been shown to induce the prolifera-
tion, survival, migration and invasion of breast cancer cell lines
in vitro and to increase the clonogenicity of primary human
breast cancer samples in soft agar [1-5]. A prolactin excess
reduces the tumour latency and increases the tumour inci-
dence and growth rate in multiple rodent models of spontane-
ous and carcinogen-induced mammary tumours [6-8]. In
humans, prospective case–control studies show that women
with high versus low blood prolactin levels have an increased
risk of preinvasive and invasive breast cancer [9,10]. Further-
more, the majority of human breast cancers have been shown
to express the prolactin receptor (PRLR) [11].
Despite these observations, attempts to treat advanced breast
cancer through the pharmacological inhibition of pituitary pro-
lactin secretion, either as monotherapy or in combination with
tamoxifen, have been disappointing. In a recent study of
women with metastatic breast cancer, however, a significant
increase in the objective tumour response rate was seen when
the dopamine agonist cabergoline was added to docetaxel
versus treatment with docetaxel alone (31/34 versus 13/36, P
Δ1–9 = Δ1–9-G129R-hPrl; BSA = bovine serum albumin; CFE = colony-forming efficiency; DCIS = ductal carcinoma in situ; DMEM = Dulbecco's 
modified Eagle's medium; FCS = foetal calf serum; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; PRLR = prolactin receptor; 
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< 0.05), suggesting that endocrine prolactin protects against
chemotherapy-induced cell death [12]. This corroborates pre-
clinical data in breast and ovarian cancers and myeloma in
which exogenous prolactin reduced the apoptotic response to
commonly used cytotoxic agents [13-15]. Furthermore, breast
cancer cell lines engineered to overexpress autocrine prolac-
tin are resistant to taxane-mediated cell death both in vitro and
in tumour xenografts in vivo [16].
Expression of prolactin has been demonstrated by in situ
hybridisation and immunostaining in the epithelial component
of over 90% of human breast cancer samples. Moreover, mul-
tiple breast cancer cell lines have been shown to synthesise
and secrete bioactive prolactin in vitro [17,18]. Coexpression
of the PRLR in breast cancer cells suggests that such prolac-
tin may act in an autocrine/paracrine fashion to influence cell
growth and survival. Approaches to antagonise autocrine pro-
lactin in breast cancer cell lines have centred on prolactin-neu-
tralising antibodies and PRLR antagonists. Neutralising
prolactin antibodies have been shown to inhibit MCF-7 and
T47Dco cell growth by 20% to 85% and to increase cell death
twofold to threefold; however, no in vivo data have been
reported on this approach [15,17]. In the latter study, prolactin
neutralisation also resulted in additive augmentation of the
apoptotic effects of exogenous ceramide [15].
The human PRLR antagonist G129R-hPRL was developed by
site-directed mutagenesis, with the substitution of glycine for
arginine at position 129 in the third alpha helix [19]. This muta-
tion sterically hinders the sequential dimerisation and subse-
quent activation of the PRLR, but notably reduces the PRLR
binding affinity 10-fold. G129R-hPRL has been shown to
reduce Bcl2 expression and to induce apoptosis in both oes-
trogen receptor-positive and oestrogen receptor-negative
breast cancer cell lines by one group, but this was not repli-
cated by others [20,21]. Administration of G129R-hPRL
reduced the growth of MCF-7 and T47D xenografts by 40% in
immunocompromised mice compared with control mice, and
its transgenic expression reduced the incidence of DMBA-
induced mammary tumours by 50% [22].
The single G129R mutation does not remove all agonist activ-
ity, however, as demonstrated by high sensitivity assays in
vitro and in the prostate gland in vivo, where G129R-hPRL
was overexpressed using the metallothionein promoter [23].
These transgenic animals exhibited hypertrophied prostate
glands with increased levels of activated mitogen-activated
protein kinase compared with those from wildtype mice. Fur-
ther modification of G129R by its N-terminal truncation results
in a 'pure' PRLR antagonist, Δ1–9 G129R-hPRL (Δ1–9),
which is devoid of any agonist activity. Coinjection of female
Balb-c/J mice with Δ1–9 and exogenous prolactin reduced the
prolactin-induced activation of STAT3 and STAT5 but only at
an antagonist/prolactin ratio of 100:1. This confirms the antag-
onistic properties of Δ1–9 but also highlights the reduced
binding affinity for the PRLR [23]. No further data are pub-
lished on Δ1–9 in breast cancer, however it has been shown
to induce apoptosis in prostate cancer cell lines by antagonis-
ing autocrine prolactin-mediated janus kinase 2 (JAK2)/
STAT5A/B signalling [24].
In the current study we examined the effects of the 'pure' pro-
lactin receptor antagonist Δ1–9 in breast cancer models in
vitro. Although ineffective at inhibiting breast cancer cell line
growth in monolayer culture as a single agent, Δ1–9 signifi-
cantly augmented the cytotoxic effects of doxorubicin and
paclitaxel. Short-term treatment with doxorubicin increased
prolactin mRNA expression in all five cell lines tested. In addi-
tion, we demonstrate for the first time that prolactin receptor
antagonism markedly inhibited the colony forming efficiency of
cell lines and primary cancers in vitro. These data suggest a
role for autocrine prolactin signalling in a subpopulation of clo-
nogenic and treatment-resistant breast cancer cells that may
be responsible for relapse after chemotherapy.
Materials and methods
Materials
Recombinant prolactin and Δ1–9 were produced in
Escherichia coli as previously described and were gifts from
V. Goffin, Necker, Paris, France [23]. MCF-7 and T47D (estro-
gen receptor alpha-positive) breast cancer cell lines and MDA-
MB-453, MDA-MB-468 and SK-BR-3 (estrogen receptor
alpha-negative) breast cancer cell lines were obtained from
the European Collection of Cell Cultures (Porton Down, Salis-
bury, UK), and were maintained in DMEM (Invitrogen, Paisley,
UK) supplemented with 10% FCS, 2 mM L-glutamine and 100
U/ml penicillin and streptomycin. Experimental media was phe-
nol red free and contained 10% dextran-coated charcoal
stripped serum unless otherwise indicated.
Cell lines were cultured in experimental medium for 48 hours
before the initiation of experiments. Doxorubicin was diluted in
normal saline and paclitaxel was diluted in dimethylsulphoxide.
Equal concentrations of the diluents were used in controls, to
a maximum dimethylsulphoxide concentration of 0.01% (at a
paclitaxel dose of 1 μM), which had no effect on cell number
compared with the experimental medium alone (data not
shown).
Sulphorhodamine B assay of cell number
The effects of Δ1–9 and cytotoxic agents on the cell number
in monolayer culture were assessed using the sulphorhodam-
ine B assay as described previously [25]. In brief, cells were
seeded in 96-well plates, allowed to adhere for 24 hours and
were treated with the desired experimental media, which was
refreshed every 2 to 3 days. At harvest, monolayers were fixed
with 10% trichloroacetic acid, washed and stained with 0.4%
sulphorhodamine B in 1% acetic acid. Sulphorhodamine B
was solubilised with 10 mM Tris base and the optical density
read at 540 nm (Molecular Devices, Sunnyvale, CA, USA).Available online http://breast-cancer-research.com/content/10/4/R68
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Correlation coefficients for optical density versus cell number
plated at 24 hours were >0.995 for all cell lines.
Assessment of clonogenic growth in soft agar
A sandwich technique was used in which 1.5 ml of 1% high-
melting-point Seakem GTG agar in PBS was poured into each
well of a six-well plate and allowed to set for 10 to 20 minutes
at room temperature. Breast cancer cell suspensions were
drawn through a 24-gauge needle (0.45 mm) five to ten times
to generate single-cell suspensions, before counting and re-
suspension in agar in experimental media to achieve a final
agar concentration of 0.3%. Two millilitres of the cell/agar mix-
ture was added to each base layer and allowed to set for 10
to 20 minutes at room temperature before incubation at 37°C.
Colonies >100 μm were counted after 14 to 21 days using an
inverter microscope (Olympus UK Ltd, Watford Hertfordshire,
UK). The colony-forming efficiency (CFE) was calculated as
number of colonies/number of cells plated (%).
Patients, ductal carcinoma in situ tissue and 
mammosphere assay
Ethical approval for the use of primary ductal carcinoma in situ
(DCIS) samples was obtained from the South Manchester
Local Regional Ethics Committee. Patients undergoing mas-
tectomy following a diagnosis of DCIS gave fully informed con-
sent for a sample of tumour to be excised and used in this
research.
Excised samples were processed as previously described
with minor modifications [26]. Samples were transferred
immediately, dissected into 3-mm to 5-mm cubes and
digested for 16 to 18 hours at 37°C in serum-free DMEM con-
taining 200 U/ml type I collagenase (Worthington Biochemical
Corporation, Lakewood, NJ, USA). The enzymatically digested
tissue was then filtered sequentially through sterile 100-μm
and 53-μm nylon meshes to obtain a single-cell suspension.
The cells were then washed three times in DMEM:F12
medium and were resuspended in mammosphere culture
medium comprising DMEM:F12 with the serum replacement
supplement B27 (Invitrogen, Paisley, UK) and hydrocortisone,
insulin, epidermal growth factor and bovine pituitary extract
(SingleQuots; Cambrex Bio Science, Nottingham, UK). Cells
were plated at a density of 500 cells/cm2 into the wells of mul-
tiwell plates that had been coated with poly(2-hydroxyethyl
methacrylate) to prevent adhesion. Colonies >60 μm were
counted after 3 days of culture.
Detection of prolactin mRNA by RT-PCR
RNA was extracted from breast cancer monolayers using TRI-
zol™ reagent according to the manufacturer's instructions (Inv-
itrogen) and was reverse transcribed using the MMLVRT
enzyme. Intron spanning oligonucleotide primers were
designed for prolactin (forward, 5'-TGCCAGGTGACCCTTC-
GAGACCTG-3'; and reverse, 5'-GACTATCAGCTCCAT-
GCCCTCTAG-3') and for the housekeeping gene acidic
ribosomal phosphoprotein P0 (forward, 5'-TGGAAGTC-
CAACTACTTCCT-3'; and reverse, 5'-GAGAAGACCTC-
CTTTTTCCA-3').
PCRs were performed with Jump-start™ Red-Taq™ DNA
polymerase (Sigma, Poole, UK). The PCR products were run
on 2% agarose gels containing 0.5 μg/ml ethidium bromide
and were visualised under UV illumination.
Western analysis of proteins extracted from cell lysates 
and conditioned media
Monolayer cultures were placed on ice and the cells were
washed with ice-cold stopping buffer (100 mM sodium
orthovanadate in PBS) before being lysed with buffer contain-
ing 50 mM Tris–HCl, 150 mM NaCl, 1% Nonidet P40, 2 mM
ethylenediamine tetraacetic acid, 1 mM sodium orthovanad-
ate, 1 mM phenylmethylsulfonylfluoride, 10 mM NaF and a
Complete™ mini protease inhibitor tablet (Roche Diagnostics
Ltd, Burgess Hill, West Sussex, UK). Cells were scraped and
suspensions placed on ice for 15 to 20 minutes. Cell debris
was pelleted by centrifugation at 14,000 rpm for 15 minutes
at 4°C. Protein concentrations of the supernatant were deter-
mined using the Bio-Rad protein assay according to the man-
ufacturers' instructions (Bio-Rad Laboratories, Hercules, CA,
USA), and lysates were boiled for 5 minutes in 'lane marker 5×
reducing sample buffer' according to the manufacturer's
instructions (Pierce Biotechnology, Cramlington, Northumber-
land, UK). The 5× buffer was used to facilitate loading of
greater concentrations of protein lysate and volumes of condi-
tioned media for electrophoresis.
For conditioned media experiments, approximately 3 million
cells were cultured in 5 ml experimental medium per flask.
Cells were treated with doxorubicin 1 μM for 8 or 24 hours
before the experimental medium was removed and the cells
washed in fresh medium containing 10% charcoal stripped
serum. A further 5 ml medium was then added prior to harvest
40 or 24 hours later (that is, 48 hours from the start of the
experiment). The conditioned media samples were centrifuged
at 14,000 rpm for 15 minutes at 4°C to remove contaminants
and were boiled in sample buffer at a 4:1 ratio for 5 minutes.
Conditioned media (40 μl) (and 10 μl sample buffer) or the
required concentration of protein were electrophoresed on
10% to 12% polyacrylamide gels according to the method of
Laemmli [27], and were transferred to nitrocellulose mem-
branes. Nonspecific binding was blocked with 5% fat-free milk
in Tris-buffered saline containing 0.1% Tween-20, before
overnight incubation at 4°C with the primary prolactin antibody
(1:100 clone 127813; R&D Systems, Abingdon, UK) diluted
in 3% fat-free milk in Tris-buffered saline containing 0.1%
Tween-20. Blots were washed three times in Tris-buffered
saline containing 0.1% Tween-20 before goat anti-mouse sec-
ondary antibody (1:1000; Autogen Bioclear UK Ltd, Calne,
Wiltshire, UK) incubation for 1 hour at room temperature.Breast Cancer Research    Vol 10 No 4    Howell et al.
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Immunoblots were developed using Supersignal West Pico
chemiluminescent substrate (Pierce Biotechnology) accord-
ing to the manufacturer's instructions, and images captured on
a Chemi-8000 cooled image digital camera (UVP Ltd, Cam-
bridge, UK).
Dual-label fluorescence immunocytochemistry
Cell lines were seeded into the wells of eight-well chamber
slides at a density of 50,000 cells/well and were allowed to
adhere for 48 hours. Cells were fixed in 4% formalin in PBS for
15 minutes and cell membranes were permeablised with 0.1%
Triton X-100 in PBS. Nonspecific binding sites were blocked
with 10% goat serum in PBS containing 1% BSA. The prolac-
tin antibody (clone 127813; R&D Systems) was labelled with
green fluorescent Alexa Fluor according to the manufacturer's
instructions (Zenon Mouse IgG Labelling kit; Molecular
Probes, Paisley, UK).
Unlabelled PRLR primary antibody (clone B6.2; Neomarkers,
Fremont, CA, USA) was applied to the cells first at a concen-
tration of 1:100 for 1 hour at room temperature followed by a
Texas red conjugated goat anti-mouse secondary antibody
(1:1000; Autogen Bioclear UK Ltd, Calne, Wiltshire, UK) for 1
hour at room temperature in the dark. The Alexa Fluor-labelled
prolactin antibody was then added (1:100) for 30 minutes at
room temperature in the dark. Negative controls consisted of
native and Alexa Fluor-labelled isotype-specific mouse IgG
incubated under identical conditions.
Slides were mounted using Vectorshield fluorescent mounting
fluid containing 4',6-diamidino-2-phenylindole to counterstain
cell nuclei. Stained cell monolayers were examined using a
Zeiss Axioscope microscope and the images were captured
using a Nikon camera and Meta Vue software (Universal Imag-
ing, Downington, PA, USA). Exposure times for each filter (red,
green and blue) were standardised across all cell lines and
negative controls.
Results and discussion
The capacity of Δ1–9 to antagonise the effects of exogenous
prolactin on activation of its downstream signalling intermedi-
ates and growth was confirmed in T47D cells (Figure 1a,b). At
the exogenous prolactin concentrations employed, a 10-fold
excess of Δ1–9 was required for almost complete antagonism
of prolactin-induced stimulation. This necessity is consistent
with data demonstrating a 10-fold reduced binding affinity of
site 2 mutated lactogenic hormones for their cognate recep-
tors, compared with their native ligands [23]. In the develop-
ment of the growth hormone receptor antagonist Peg-
Visomant (Somavert™), this need was overcome by further
engineering the site 1 binding site, with eight additional amino
acid substitutions, restoring the receptor binding affinity to that
of native growth hormone [28]. A similar approach to increase
the binding affinity of the PRLR antagonists to the PRLR would
be required if they are to be developed successfully as thera-
peutic agents.
In the absence of exogenous human prolactin, Δ1–9 had no
effect on the T47D and MCF-7 cell numbers in monolayer cul-
ture over 10 days (Figure 1c). At Δ1–9 concentrations
Figure 1
Δ1–9-G129R-hPrl inhibits exogenous prolactin effects but does not  reduce cell numbers in standard growth conditions Δ1–9-G129R-hPrl inhibits exogenous prolactin effects but does not 
reduce cell numbers in standard growth conditions. (a) Western analy-
sis of T47D cell lysates confirms prolactin (500 ng/ml for 30 min) 
induced phosphorylation of STAT 5A/B, which is abrogated in a dose-
dependent manner by coincubation with Δ1–9-G129R-hPrl (Δ1–9). (b) 
Prolactin-induced increase in cell number of T47D cells in monolayer 
culture for 3 days was abrogated by coincubation with Δ1–9. (c) 1,000 
ng/ml Δ1–9 (broken lines) had no effect on cell number in control 
medium (solid lines) of MCF-7 cells (upper two curves) or T47D cells 
(lower two curves) in a monolayer culture in the absence of exogenous 
prolactin. *P < 0.05 by Student t test compared with 100 ng/ml prolac-
tin in the absence of Δ1–9. Error bars, standard error of the mean of 
triplicate observations. All data representative of at least three 
experiments.Available online http://breast-cancer-research.com/content/10/4/R68
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between 1 and 10,000 ng/ml in 2-day to 10-day assays in
media containing either FCS or charcoal stripped serum, no
significant effect on the cell number in a monolayer of any of
the five breast cancer cell lines tested (MCF-7, T47D, MDA-
MB-453, MDA-MB-468 and SKBR3) could be demonstrated
(data not shown). The lack of activity of this PRLR antagonist
in monolayer culture is consistent with previously published
work [21]. Using similar culture conditions to ours, no effects
on cancer cell proliferation or apoptosis were seen with the
parental PRLR antagonist G129R. In contrast, using the same
antagonist, Chen and colleagues demonstrated small but sta-
tistically significant reductions in cell number in T47D and
MCF-7 cell lines correlated to an increase in apoptosis [20].
These latter data are consistent with reports of growth inhibi-
tion of breast cancer cell lines using prolactin inhibitory anti-
bodies, and it is possible that subtle variations in culture
conditions/constituents or genetic drift of the cell lines may
account for the discrepancies between our findings and those
of others [15,17,29].
In serum-free medium, the MCF-7 cell number declined over 5
days in culture and, in contrast to the findings above, Δ1–9
induced further significant reductions in the MCF-7 cell
number of 5% to 10% over controls, at concentrations >10
ng/ml (Figure 2a). Using RT-PCR, a time-dependent increase
in prolactin mRNA expression was seen in response to serum
starvation, leading to the hypothesis that autocrine prolactin is
produced to promote survival of breast cancer cells under
conditions of stress, and that its antagonism reduces cell sur-
vival (Figure 2b). To examine the effects of more therapeuti-
cally relevant stressors, MCF-7 cells were exposed to 1 μM
doxorubicin for 24 hours before RNA extraction. Doxorubicin
treatment was associated with an increase in prolactin mRNA
expression, which was sustained for at least 5 days after treat-
ment, whereas it could not be detected in cells cultured in con-
trol medium (Figure 2c).
All five of the breast cancer cell lines tested demonstrated
increased prolactin mRNA expression after a 24-hour expo-
sure to 1 μM doxorubicin compared with untreated cells (Fig-
ure 2d). The increases in prolactin mRNA were accompanied
by increases in prolactin protein secretion, as demonstrated
by western analysis of the conditioned medium from these
cells (Figure 2e). Prolactin was secreted into the medium at
concentrations between 2 and 20 ng/ml following doxorubicin
treatment, with increased secretion evident with treatment for
24 hours. As approximately 3 million cells were used in 5 ml
medium (see Materials and methods) and the amount of prol-
actin produced by the cells is taken as approximately 5 ng/ml,
this secretion equates to ~25 ng/3 × 106 cells/24 hours,
which is equivalent to ~8 pg/cell/24 hours. This level is com-
parable with the results of Ginsburg and Vonderhaar, who
detected 7 to 14 pg/cell/24 hours in T47Dco cells as
assessed by the Nb2 bioassay using concentrated condi-
tioned media [17]. No prolactin was detected in the cell
Figure 2
Autocrine prolactin production is stimulated by serum starvation and  treatment with doxorubicin Autocrine prolactin production is stimulated by serum starvation and 
treatment with doxorubicin. (a) Monolayer culture of MCF-7 cells in 
serum-free medium over 5 days (open bars) resulted in cell loss com-
pared with the cell number at 24 hours after plating in 10% charcoal 
stripped serum (CSS) (grey bar). Δ1–9-G129R-hPrl (Δ1–9) increased 
cell loss in a dose-dependent manner (clear bars). Prolactin (PRL) 
mRNA was detected in MCF-7 cells by RT-PCR in response to (b) 
serum starvation and (c) treatment with 1 μM doxorubicin for 24 hours, 
but not in cells grown in control medium (10% CSS). ARPP0, acidic 
ribosomal phosphoprotein P0; SFM, serum free medium. Following 
doxorubicin treatment for 24 hours, cultures were washed and fresh 
control medium was added. Times correspond to the number of hours 
from the start of the experiment. (d) All five cell lines were treated with 
doxorubicin (DOX) as in (c) and were harvested at 48 hours, and they 
demonstrate the induction of prolactin mRNA expression. ARPP0 was 
used as a housekeeping gene loading control in all RT-PCR experi-
ments. (e) Western analysis of prolactin in cell culture media. Brack-
eted lanes represent the positive control concentration curve of 
recombinant human prolactin. Other lanes are conditioned media from 
MCF-7 cells in 10% CSS alone (con) or following 1 μM doxorubicin 
treatment for 8 and 24 hours and conditioned media harvested 48 
hours after the start of the experiment.Breast Cancer Research    Vol 10 No 4    Howell et al.
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lysates prepared from these experiments (data not shown),
consistent with previous observations that prolactin is not
stored in intracellular granules in extrapituitary tissues, in con-
trast to the pituitary gland [30].
We next examined whether Δ1–9 potentiated the effects of
doxorubicin, and of the microtubule stabilising agent paclit-
axel, on cell number. Combining doxorubicin or paclitaxel at a
concentration of 1 μM with 1,000 ng/ml Δ1–9 produced small
reductions in cell number compared with chemotherapy alone,
suggesting that autocrine prolactin produced under these
conditions functions as a survival factor (Figure 3a). This effect
was seen over a range of chemotherapy doses in short-term
culture (Figure 3b,c) and also in longer term culture of cells for
10 days, after short initial pulses of doxorubicin for 2 to 12
hours (Figure 3d). Coculture with Δ1–9 significantly reduced
the cell number by 10% to 15% compared with cells grown in
control medium, irrespective of the initial doxorubicin pulse
duration. Cells that survived treatment with 1 μM doxorubicin,
to repopulate the culture dish, expressed increased levels of
prolactin mRNA compared with cells not exposed to the drug
(Figure 3e).
Previous in vitro studies have demonstrated additive effects of
antiprolactin approaches with ceramide or cytotoxic agent-
induced cell death in breast cancer cell lines [15,20]. In addi-
tion, the engineered overexpression of prolactin in the MDA-
MB-468 breast cancer cell line protected the cells from pacli-
taxel-induced apoptosis [16]. Similar observations have also
been made in ovarian cancer and prostate cancer as well as in
the plasma cell malignancy myeloma, suggesting that prolactin
may alter the sensitivity to cytotoxic agents in a wide variety of
malignancies [13,14,31].
The data presented here are the first to demonstrate that the
production of biologically relevant autocrine prolactin is
induced by chemotherapeutic agents. Interestingly, the phe-
nomenon of increased prolactin production in response to
anthracyclines has been observed in rats in vivo, albeit from
lactotrophs in the anterior pituitary gland [32]. Such chemo-
therapy-induced systemic prolactin release may help to explain
the beneficial effects of cabergoline when coadministered
with chemotherapy in women with metastatic breast cancer, in
the clinical trial cited above [12].
The soft agar assay was used to investigate the effects of Δ1–
9 on the clonogenic growth of breast cancer cell lines both
alone and after treatment with doxorubicin. Treatment of MCF-
7 cells for 2 hours with 1 μM doxorubicin in monolayer culture,
before plating them into soft agar, reduced the CFE by 61%
(P < 0.05 by unpaired Student t test; Figure 4a). The addition
of 1,000 ng/ml Δ1–9 to the doxorubicin further reduced the
CFE, resulting in a 94% reduction compared with controls (P
< 0.01) and an 84% reduction compared with doxorubicin
treatment alone (P < 0.01). In the absence of doxorubicin, Δ1–
9 pretreatment had no effect on MCF-7 CFE in soft agar (Fig-
ure 4a).
In contrast, incorporation of Δ1–9 into both layers of the agar
resulted in a marked, dose-dependent reduction in the MCF-7
CFE (Figure 4b). A maximal reduction in the CFE of 90 ± 4.2%
(mean ± standard deviation; P < 0.001) was seen at 1,000
ng/ml Δ1–9 after 14 days of culture. The MDA-MB-453 and
SKBR3 cells did not form colonies in this assay. The T47D and
MDA-MB-468 cell lines did from colonies, however, with a
similar CFE as MCF-7 cells. Δ1–9 reduced their CFEs by 89
± 3.8% and 93 ± 6.8%, respectively, at a concentration of
1,000 ng/ml (P < 0.001 for both). This dramatic effect of
PRLR antagonism in clonogenic cells but not in a monolayer
culture suggests the presence of a subpopulation of clono-
genic cells with increased dependence upon autocrine/para-
crine prolactin signalling compared with their nonclonogenic
counterparts.
The expression of both the PRLR and autocrine prolactin was
thus examined in a monolayer culture of breast cancer cell
lines by dual-label fluorescence immunocytochemistry. All
T47D cells showed strong staining for both the PRLR (red flu-
orescence) and for prolactin (green fluorescence), which
showed subcellular localisation in a region consistent with
Golgi localisation (Figure 5b). Such subcellular localisation
may explain why prolactin could be detected by immunocyto-
chemistry, due to the increased concentrations at these sites,
but not by western analysis of whole cell lysates. Western
analysis of subcellular fractions may facilitate detection of pro-
lactin from cell lysates. The staining pattern of MCF-7 cells for
the PRLR was more heterogeneous and was confined to par-
ticular colonies of cells. These cells also coexpressed prolac-
tin and were often surrounded by cells that expressed neither
prolactin nor its receptor (Figure 5c). The three oestrogen
receptor-negative cell lines displayed less frequent PRLR-pos-
itive cells compared with the oestrogen receptor-positive lines
(Figure 5d to 5f). Further work is required to correlate the rel-
ative clonogenicity of cells with expression levels of PRLR and
prolactin, and would be augmented by improvements in PRLR
antibodies to determine the relative expression levels of the
long form of the PRLR and the dominant negative short form
of the PRLR.
Only one other group has reported data on clonogenic assays
and prolactin in breast cancer cells; in their hands, prolactin
increased the CFE by up to 25% [2]. To our knowledge, the
present study is the first to demonstrate that an antiprolactin
approach can significantly reduce the colony-forming ability of
breast cancer cells in culture. Next the effects of Δ1–9 on the
clonogenicity of disaggregated primary DCIS specimens were
examined. These DCIS cells did not grow in the soft agar
assay described, so a suspension culture technique termed
the mammosphere assay was employed. This was chosen onAvailable online http://breast-cancer-research.com/content/10/4/R68
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Figure 3
Δ1–9-G129R-hPrl reduces the MCF-7 cell number in combination with doxorubicin or paclitaxel Δ1–9-G129R-hPrl reduces the MCF-7 cell number in combination with doxorubicin or paclitaxel. (a) Sulphorhodamine B assay of MCF-7 cells 
treated for 48 hours with chemotherapy or control medium (10% charcoal stripped serum (CON)) alone (empty bars) or in combination with 1,000 
ng/ml Δ1–9-G129R-hPrl (Δ1–9) (filled bars). *P < 0.05 by Student t test between paired bars. Forty-eight-hour MCF-7 dose–response curves to (b) 
doxorubicin, and (c) paclitaxel alone (▲) or in combination with 1,000 ng/ml Δ1–9 (■). (d) MCF-7 cells in monolayer culture treated with 1 μM dox-
orubicin for pulse durations of 2, 6 and 12 hours before removal of doxorubicin and subsequent culture in control medium in the absence (solid 
lines) or presence (broken lines) of 1,000 ng/ml Δ1–9. Medium was refreshed every 2 to 3 days thereafter. P < 0.05 by Student t test at 5 days (*) 
and 10 days (†). (e) MCF-7 cells treated with 1 μM doxorubicin (DOX) for 24 hours were cultured until exponential growth resumed (5 to 6 weeks) 
and were analysed for prolactin (PRL) mRNA expression. ARPP0, acidic ribosomal phosphoprotein P0.Breast Cancer Research    Vol 10 No 4    Howell et al.
Page 8 of 11
(page number not for citation purposes)
the basis that a highly tumorigenic subpopulation of primary
breast cancer cells with the properties of both self-renewal
and multipotency can be isolated by means of their capacity to
survive anoikis and to grow in suspension culture [33].
Mammospheres were generated in suspension culture from
six DCIS samples. Such mammospheres have been shown to
be of epithelial origin, as they express cytokeratins 14 and 18,
but were shown to form faster and with greater efficiency than
Figure 4
Single-agent Δ1–9-G129R-hPrl inhibits colony formation of cell lines and primary ductal carcinoma in situ samples Single-agent Δ1–9-G129R-hPrl inhibits colony formation of cell lines and primary ductal carcinoma in situ samples. (a) MCF-7 cells treated for 2 
hours in monolayer culture with control medium, Δ1–9-G129R-hPrl (Δ1–9) (1,000 ng/ml), doxorubicin (1 μM) or the combination were subsequently 
plated into soft agar (see Materials and methods) and colonies were counted at 14 days. * p < 0.05 compared to untreated control and Δ1–9 alone, 
† p < 0.01 compared to each of the other three conditions (both by Student t-test). (b) MCF-7 cells plated into soft agar with Δ1–9 incorporated into 
the agar at the concentrations shown. (c) Effects of bovine pituitary extract (BPE) and prolactin on the ductal carcinoma in situ (DCIS) mammos-
phere forming efficiency. DCIS mammospheres were counted on day 3 in complete culture medium (complete medium), complete medium without 
BPE (-BPE) and with 500 ng/ml human prolactin substituted for BPE (-BPE + PRL). Grey-filled and empty bars represent the means of duplicate 
observations from two independent samples; error bars, standard error of the mean. (d) Table of the six DCIS samples detailing their mammosphere 
forming efficiency (MFE), the maximum reduction in MFE with Δ1–9 and the concentration of Δ1–9 at which maximum inhibition was achieved. (e) 
Photomicrograph of a DCIS mammosphere following embedding in paraffin and immunohistochemical analysis for the PRLR using a Fluorescein iso-
thiocyanate (FITC)-labelled secondary antibody (green fluorescence). Cell nuclei counterstained using 4',6-diamidino-2-phenylindole (blue). Scale 
bar = 50 μm.Available online http://breast-cancer-research.com/content/10/4/R68
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those from normal breast tissue – confirming their origin from
the malignant cells rather than adjacent normal breast [26]. As
bovine pituitary extract was used in the mammosphere growth
medium, it was necessary to first investigate the effects of the
bovine prolactin content on DCIS mammosphere formation. In
the first two mammosphere assays on DCIS samples, there-
fore, controls were set up in which 500 ng/ml exogenous
human prolactin was substituted for the bovine pituitary
extract. The results demonstrate that the removal of bovine
pituitary extract reduced mammosphere formation significantly
but that human prolactin could not substitute for the effects of
bovine pituitary extract on mammosphere formation (Figure
4c). In view of these and previously published data demon-
strating the reduced affinity of bovine prolactin for the human
PRLR, we were satisfied that exogenous prolactin from bovine
pituitary extract would not interfere significantly with the
effects of Δ1–9 on autocrine prolactin signalling [17].
In all six DCIS samples tested, the mammosphere forming effi-
ciency was reduced significantly by the inclusion of Δ1–9 into
the culture medium – with maximal inhibition of mammosphere
forming efficiency at concentrations from 10 to 1,000 ng/ml
(Figure 4d). An example of inhibition is shown in Figure 4d. The
median reduction in the mammosphere forming efficiency at 3
days was 56% (range 32% to 88%). Immunohistochemistry of
paraffin-embedded DCIS mammospheres demonstrated cyto-
plasmic expression of the PRLR in cells located at their periph-
ery (Figure 4e).
We have demonstrated a disparity between the effects of Δ1–
9 in routine growth in monolayers and under conditions of cell
stress or clonogenic growth. In response to cell stressors
such as doxorubicin, signalling components known to be
downstream of the PRLR, notably Src and focal adhesion
kinase, are upregulated in cells lines [34,35]. The balance
between cell apoptosis and proliferation downstream of PRLR
signalling has been described previously to be dependent on
the relative abundance of such signalling intermediates [1,36-
38]. Changes in the abundance of signalling intermediates in
this situation could therefore induce autocrine/paracrine prol-
actin dependence and preferential survival of prolactin-
expressing cells. Furthermore, cells exhibiting such depend-
ence may be a subpopulation of clonogenic cells, antagonism
of which in a short-term monolayer culture results in no dis-
cernable change in cell number. Conditions of cell stress in
monolayer and clonogenic assays expose the relative impor-
Figure 5
Immunofluorescence of prolactin and the prolactin receptor in breast cancer cell lines Immunofluorescence of prolactin and the prolactin receptor in breast cancer cell lines. Dual-fluorescence immunocytochemistry for the prolactin 
receptor (PRLR) and prolactin in breast cancer cell lines. Cells were plated onto eight-well chamber slides at identical cell densities and were 
allowed to adhere for 48 hours prior to fixation and staining (see Materials and methods). Top row, 4',6-diamidino-2-phenylindole; second row, 
PRLR–Texas red; third row, prolactin–Fluorescein isothiocyanate (FITC) (green); fourth row, merged images. (a) Negative controls photographed 
with identical exposure and processed with identical software settings, compared with antibody-positive samples shown in subsequent columns: (b) 
T47D cells, (c) MCF-7 cells, (d) MDA-MB-468 cells, (e) MDA-MB-453 cells, and (f) SKBR3 cells.Breast Cancer Research    Vol 10 No 4    Howell et al.
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tance of these cell populations, the growth of which can be
antagonised by Δ1–9.
The mechanisms by which autocrine prolactin secretion pro-
tects breast cancer cell lines from the effects of serum
starvation and cytotoxic agents have not yet been elucidated.
Other groups have shown that overexpression of prolactin in
breast cancer cell lines induces the expression of the antiap-
optotic protein Bcl-2, and that treatment with G129R-hPrl has
been shown to reduce Bcl-2 levels whilst increasing those of
the proapoptotic protein Bax [4,39]. The inability of a second
group to repeat these findings may be due to the effect being
evident only in a subpopulation of clonogenic cells and not
their more differentiated progeny. Differences in cell culture
techniques, reagents and cell lines between laboratories may
have exacerbated these discrepancies, and these differences
highlight the need for better techniques to identify such treat-
ment-resistant subpopulations of cells.
The expression and secretion of autocrine/paracrine prolactin
mRNA and protein following chemotherapy raises the
possibility of improved breast cancer therapy with the combi-
nation of cytotoxic chemotherapy and a PRLR-targeted agent.
The increase in mRNA expression to a maximum at 48 hours,
followed by a fall in levels thereafter, suggests that
combination therapy should be given initially. The duration of
PRLR-targeted therapy would probably be at least 1 week as
mRNA was detectable up to this point. Investigation of longer
term prolactin mRNA expression post treatment was not inves-
tigated, however, and the most efficacious treatment regimens
will need to be discerned from further in vitro studies and
xenograft studies in vivo.
Conclusion
In contrast to its lack of effect in monolayer culture, PRLR
antagonism with Δ1–9 profoundly inhibits colony formation of
both breast cancer cell lines and primary tumour samples. This
suggests the presence of a clonogenic population of breast
cancer cells that are preferentially sensitive to prolactin inhibi-
tion. In addition, autocrine/paracrine prolactin appears to be a
survival factor in this subpopulation of breast cancer cells and
is induced by treatment with doxorubicin or paclitaxel, as treat-
ment with the PRLR antagonist Δ1–9 potentiates the efficacy
of such drugs. If autocrine prolactin is preferentially produced
by a cytotoxic-resistant putative breast cancer stem cell, then
the rational combination of cytotoxic agents and Δ1–9 may
improve outcomes in breast cancer therapy.
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